Acer Therapeutics appoints chief medical officer

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
WebinarM&A In Focus: Tech Acquisitions and the ‘New Normal’ in 2023
- 02/08/2023
- Live, Online
- 11:00 am - 12:00 pm EST
Webinar ReplaysAssessing the impact of the U.S. Government Accountability Office recommendations’ on Export Control Compliance at universities
- 01/18/2023
- On-Demand
- 60 minutes
ConferenceTPMTech
- 02/23/2023
- Hilton Long Beach Convention Center
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism

5 Oct, 2017 | 20:14

Author Mirza Salam Ahmed
Theme Healthcare & Pharmaceuticals

Acer Therapeutics Inc., which has merged with Opexa Therapeutics Inc., appointed William Andrews as chief medical officer to replace Robert Steiner.

Previously, Andrews held senior leadership positions and positions of increasing responsibility at Aegerion Pharmaceuticals Inc., Santhera Pharmaceuticals Holding AG, Sepracor, and ClinQuest.